Ravi Salgia to Signal Transduction
This is a "connection" page, showing publications Ravi Salgia has written about Signal Transduction.
Connection Strength
3.509
-
Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433.
Score: 0.229
-
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77.
Score: 0.144
-
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70.
Score: 0.138
-
Molecular and cellular biology of small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):57-71.
Score: 0.106
-
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med. 2002 Oct-Dec; 6(4):539-53.
Score: 0.103
-
RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. Carcinogenesis. 2021 05 28; 42(5):742-752.
Score: 0.094
-
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
Score: 0.092
-
Activating p53 function by targeting RLIP. Biochim Biophys Acta Rev Cancer. 2021 04; 1875(2):188512.
Score: 0.092
-
MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
Score: 0.088
-
RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. Biochim Biophys Acta Rev Cancer. 2020 01; 1873(1):188337.
Score: 0.085
-
Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog. 2000; 11(1):63-76.
Score: 0.085
-
Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells. Leukemia. 1998 May; 12(5):637-44.
Score: 0.076
-
EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137.
Score: 0.075
-
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
Score: 0.070
-
Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog. 1997; 8(4):343-58.
Score: 0.069
-
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
Score: 0.068
-
FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016 May 24; 7(21):31586-601.
Score: 0.066
-
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
Score: 0.064
-
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
Score: 0.062
-
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med. 2014 Jun; 3(3):681-92.
Score: 0.057
-
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem. 2014 May 09; 289(19):13476-91.
Score: 0.057
-
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
Score: 0.056
-
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23.
Score: 0.055
-
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One. 2013; 8(7):e67668.
Score: 0.054
-
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
Score: 0.051
-
A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906.
Score: 0.049
-
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011 Dec; 1(7):573-9.
Score: 0.049
-
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010 Oct 15; 285(42):32596-605.
Score: 0.044
-
The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther. 2010 Mar 15; 9(6):409-16.
Score: 0.043
-
MET receptor tyrosine kinase. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1064-5.
Score: 0.042
-
MET pathway as a therapeutic target. J Thorac Oncol. 2009 Apr; 4(4):444-7.
Score: 0.040
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.040
-
Non-receptor tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med Chem. 2007 Nov; 7(6):633-42.
Score: 0.037
-
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal. 2007 Nov; 19(11):2329-38.
Score: 0.036
-
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
Score: 0.035
-
Key signaling pathways and targets in lung cancer therapy. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S52-60.
Score: 0.035
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.032
-
Molecular biology of malignant mesothelioma: a review. Hematol Oncol Clin North Am. 2005 Dec; 19(6):997-1023, v.
Score: 0.032
-
A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 2005 Mar 15; 11(6):2312-9.
Score: 0.031
-
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
Score: 0.030
-
The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004 Dec; 15(6):419-33.
Score: 0.030
-
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005 Feb 15; 105(4):1717-23.
Score: 0.030
-
Targeting c-Kit mutations: basic science to novel therapies. Leuk Res. 2004 May; 28 Suppl 1:S11-20.
Score: 0.029
-
Novel targets for therapeutic agents in small cell lung cancer. J Natl Compr Canc Netw. 2004 Mar; 2(2):165-72.
Score: 0.028
-
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer. J Environ Pathol Toxicol Oncol. 2004; 23(4):237-51.
Score: 0.028
-
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003 Dec; 22(4):309-25.
Score: 0.028
-
Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochem Pharmacol. 2023 11; 217:115847.
Score: 0.028
-
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res. 2003 Oct 01; 63(19):6272-81.
Score: 0.028
-
Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J Cell Mol Med. 2003 Apr-Jun; 7(2):157-64.
Score: 0.027
-
Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
Score: 0.026
-
Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002 Nov 01; 62(21):6304-11.
Score: 0.026
-
Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
Score: 0.025
-
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):620-7.
Score: 0.025
-
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
Score: 0.022
-
Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020 08 01; 484:16-28.
Score: 0.022
-
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167.
Score: 0.021
-
Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Lett. 2019 10 01; 461:123-131.
Score: 0.021
-
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood. 1999 May 01; 93(9):2928-35.
Score: 0.020
-
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Mol Carcinog. 2018 12; 57(12):1751-1762.
Score: 0.020
-
Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
Score: 0.019
-
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 1997 Dec; 28(1-2):65-72.
Score: 0.018
-
Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer. 2017 08 15; 141(4):766-777.
Score: 0.018
-
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem. 1997 May 30; 272(22):14320-6.
Score: 0.018
-
Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997 Apr; 171(1):28-33.
Score: 0.018
-
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 1997 Mar; 8(1):63-79.
Score: 0.018
-
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem. 1997 Feb 14; 272(7):4230-6.
Score: 0.017
-
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation. Exp Hematol. 1997 Jan; 25(1):45-50.
Score: 0.017
-
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem. 1996 Oct 11; 271(41):25198-203.
Score: 0.017
-
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
Score: 0.017
-
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
Score: 0.015
-
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3):e91577.
Score: 0.014
-
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68.
Score: 0.014
-
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
Score: 0.014
-
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J. 2011 Oct 01; 439(1):45-55.
Score: 0.012
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.012
-
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
Score: 0.012
-
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002 Sep 15; 62(18):5242-7.
Score: 0.006
-
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002 Mar 08; 277(10):7875-81.
Score: 0.006
-
SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. J Biol Chem. 2001 Jan 26; 276(4):2451-8.
Score: 0.006
-
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000 Aug 11; 275(32):24273-8.
Score: 0.006
-
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem. 1999 Dec 17; 274(51):36684-92.
Score: 0.005
-
Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. 1999 Jun 03; 18(22):3343-53.
Score: 0.005
-
A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion. EMBO J. 1998 Dec 15; 17(24):7320-36.
Score: 0.005
-
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.
Score: 0.004